Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer (OCEDP)
Ovarian Cancer Early Detection Screening Program
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98122
- Marsha Rivkin Center for Ovarian Cancer Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Must meet one of the following:
- The family contains at least two ovarian or breast cancers in the subject or first or second degree relatives of the subject.
- The subject is of Ashkenazi Jewish ethnicity with one first degree or two second-degree relatives with breast or ovarian cancer, or subject is of Ashkenazi ancestry and has had breast cancer.
- The subject has a male relative with breast cancer diagnosed at any age.
- Probability of carrying a BRCA1/2 mutation given family pedigree of breast and ovarian cancers exceeds 20% (as determined by BRCAPRO 95% posterior probability interval).
Exclusion Criteria:
- Prior ovarian cancer or peritoneal carcinomatosis
- A first or second degree relative with a BRCA1/2 mutation and has tested negative for exactly the same mutation.
- The subject has no ovaries.
- Less than 30 years of age, unless 25-30 with BRCA I or II mutation confirmed
- Currently pregnant
- Currently receiving adjuvant chemotherapy or radiation therapy for cancer (excluding tamoxifen). Patients who are being treated for local disease may enroll 3 months after completion of last treatment (excluding tamoxifen).
- Treatment (excluding tamoxifen) for prior metastatic malignancy within the past five years.
- Intraperitoneal surgery within the last 3 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Ovarian Cancer Screening
CA125 tumor marker, Transvaginal Ultrasound, Health Status Questionnaires
|
Performed every 6 months, these blood samples will be drawn to measure the concentration of CA125 tumor marker.
Remaining samples will be stored in a specimen repository for use in future research for ovarian and breast cancer tumor markers.
Performed annually, these pelvic ultrasounds will be used used to look for 1) enlargement of one or both ovaries or 2) suspicious or indeterminate morphometric parameters, determined by the presence of intracystic papillations, and/or mural nodularity.
Performed every 6 months, these questionnaires will ask about your health and medical history, environmental exposures, and family history.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Measuring for elevated levels of tumor marker CA-125 in the blood over time.
Time Frame: Average expected time of 1 year
|
Average expected time of 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Performing transvaginal ultrasounds to look for any abnormalities over time.
Time Frame: Average expected time of 1 year
|
Criteria for an abnormal scan include 1) enlargement of one or both ovaries or 2) suspicious or indeterminate morphometric parameters, determined by the presence of intracystic papillations, and/or mural nodularity.
Volume calculations will determine whether the ovary is enlarged.
|
Average expected time of 1 year
|
|
Performing health status questionnaires over time
Time Frame: Average expected time of 1 year
|
Average expected time of 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Pamela Paley, MD, Swedish Medical Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Ovarian Diseases
Other Study ID Numbers
Other Study ID Numbers
- IR 4707
- CRC 08108 (Other Identifier: Swedish Medical Center)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.